Universal CLL1 CAR-T cell therapy for relapsed or refractory AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new treatment called universal CLL1 CAR-T cells for people whose acute myeloid leukemia (AML) has come back or hasn't responded to standard treatments. It aims to see if these specially designed immune cells can find and attack leukemia cells that carry a marker called CLL1.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have AML that has returned after treatment or has not responded to two or more standard treatments.
- At least half of your leukemia cells must have the CLL1 marker.
- You need to have a donor available for a stem cell transplant if needed.
- You should be in fairly good health, with an ECOG score of 0 or 1 (able to do daily activities).
- Your kidney, liver, heart, and lung function must meet certain minimum levels.
- You must agree to use effective birth control if there is a chance of pregnancy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a type of immunotherapy called CAR-T cells that are made to target leukemia cells. The cells are designed to attack AML by recognizing several proteins on the cancer cells, and may be an option for patients who have not responded well to other treatments.
This study tests a new CAR-T cell therapy that targets two proteins, CLL1 and CD38, on leukemia cells. It is designed for people whose acute myeloid leukemia has returned or not responded to treatment.
This trial tests a lab-made immune cell treatment (CAR-T) made to target AML cells with a specific marker (NKG2D ligand). It’s for people whose acute myeloid leukemia (AML) has come back or didn’t respond to standard chemotherapy.
This trial tests a new treatment using your donor's immune cells that are engineered to find and attack cancer cells with a specific marker called CD117. It's for people with acute myeloid leukemia (AML) that has come back or not responded to standard treatments.
This trial tests a therapy made from your own immune cells, engineered to target a marker called CLL-1 on leukemia cells, for people whose AML has come back or hasn't responded to standard treatments.
This trial tests a new type of immune cell therapy (CAR-T) designed to find and kill leukemia cells that carry two specific markers (CLL-1 and CD33). It is for adults with acute myeloid leukemia that has come back or is not responding to standard treatments.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.